Data suggest that CD19-directed CAR T-cell therapy may be curative for patients with relapsed or refractory CLL who maintain a response for at least 1 year.
Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback